Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that ...

Researchers say semaglutide may help reverse MASH, a progressive liver condition affecting millions of Americans.

A groundbreaking international study has found that semaglutide a widely used anti-diabetic drug can halt and even reverse advanced liver disease in patients suffering from metabolic dysfunction ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

FAT jabs like Ozempic are set to get the seal of approval from the World Health Organisation (WHO). This would back the use ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), ...

New research has revealed that the injections for weight loss might be doing something much bigger inside your body.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...